Misplaced Pages

HT-0712: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 11:00, 2 December 2010 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:Wi← Previous edit Revision as of 06:52, 2 February 2011 edit undo72.199.145.236 (talk)No edit summaryNext edit →
Line 37: Line 37:
}} }}


'''HT-0712''' is an experimental ] enhancing ] (]) which is currently undergoing ]. It is currently being licensed by Helicon Therapeutics in Cleveland, Ohio. It was originally discovered and tested as part of a preclinical anti-inflammatory program by Inflazyme Pharmaceuticals. '''HT-0712''' is an experimental ] enhancing ] (]) which is currently undergoing ]. It is currently being licensed by Helicon Therapeutics in San Diego, California. It was originally discovered and tested as part of a preclinical anti-inflammatory program by Inflazyme Pharmaceuticals.


==Mechanism of action== ==Mechanism of action==

Revision as of 06:52, 2 February 2011

Pharmaceutical compound
HT-0712
File:HT-0712.png
Clinical data
Other namesHT-0712, IPL 455,903
Identifiers
IUPAC name
  • (3R,5R)-5-(3-(cyclopentyloxy)-4-methoxyphenyl)-3-(3-methylbenzyl)piperidin-2-one
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC25H31NO3
Molar mass393.53 g/mol g·mol
3D model (JSmol)
SMILES
  • O=C3NC(c2cc(OC1CCCC1)c(OC)cc2)C3Cc4cccc(c4)C
InChI
  • InChI=1S/C25H31NO3/c1-17-6-5-7-18(12-17)13-20-14-21(16-26-25(20)27)19-10-11-23(28-2)24(15-19)29-22-8-3-4-9-22/h5-7,10-12,15,20-22H,3-4,8-9,13-14,16H2,1-2H3,(H,26,27)/t20-,21-/m1/s1
  • Key:ABEJDMOBAFLQNJ-NHCUHLMSSA-N
  (verify)

HT-0712 is an experimental cognitive enhancing drug (nootropic) which is currently undergoing clinical trials. It is currently being licensed by Helicon Therapeutics in San Diego, California. It was originally discovered and tested as part of a preclinical anti-inflammatory program by Inflazyme Pharmaceuticals.

Mechanism of action

HT-0712 appears to act as a PDE4 inhibitor, thereby increasing cAMP levels. When cAMP levels are increased in neurons, this may trigger activation of cAMP response element-binding proteins (CREB). CREBs are transcription factors involved in the formation of long-term memory.

The side effects of the drug are not yet fully known.

Medical use

Middle-aged people, seniors, and possibly those suffering from dementia, who have a hard time remembering everyday events, can possibly benefit from this drug.

Performance enhancing use

Many students may be inclined to use nootropics for school and college life for exams and finals. This could also be an effective alternative or adjunctive to the use of caffeine as a study aid.

References

United States Patent 20040224316

External links


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Phosphodiesterase inhibitors
PDE1
PDE2
PDE3
PDE4
PDE5
PDE7
PDE9
PDE10
PDE11BC11-38
Non-selective
Unsorted
See also: Receptor/signaling modulators
Categories: